Moreover, it has been demonstrated that PDZ1, an SDCBP target-specific small-molecule inhibitor, displays therapeutic potential for prostate cancer and potentially other cancers expressing elevated levels of SDCBP [62]. This evidence concerns the gene SDCBP and cancer.